CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Do analysts recommend CASI or TARA?

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 69.49%. Protara Therapeutics has a consensus price target of $19.60, indicating a potential upside of 530.23%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Protara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Which has higher earnings and valuation, CASI or TARA?

CASI Pharmaceuticals has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	1.02	-$39.26M	-$2.55	-0.93
Protara Therapeutics	N/A	N/A	-$44.60M	-$1.62	-1.92

Which has more volatility and risk, CASI or TARA?

CASI Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Is CASI or TARA more profitable?

Protara Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Protara Therapeutics' return on equity of -36.87% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
Protara Therapeutics	N/A	-36.87%	-33.85%

Do institutionals and insiders have more ownership in CASI or TARA?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer CASI or TARA?

In the previous week, Protara Therapeutics had 6 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 6 mentions for Protara Therapeutics and 0 mentions for CASI Pharmaceuticals. Protara Therapeutics' average media sentiment score of 0.45 beat CASI Pharmaceuticals' score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Protara Therapeutics	Neutral

Summary

Protara Therapeutics beats CASI Pharmaceuticals on 12 of the 16 factors compared between the two stocks.